Study Confirms Zytiga's Benefit in Earlier-Stage Prostate Cancer
By Nuala Moran
Tuesday, December 11, 2012
Scientists at the Institute of Cancer Research published details of the Phase III trial of Johnson & Johnson's prostate cancer drug Zytiga in men who had not received chemotherapy, a day after the FDA agreed to a label extension allowing the drug to be used at that earlier stage of the disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.